The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis, and provide a reference for clinical treatment timing.
Aged 18 to 75 years old;
Patients with intracerebral hemorrhage (NIHSS ≥5 points);
No history of cerebrovascular diseases with residual functional impairment before brain injury;
Hospitalized within 72 hours after injury;
Patients with severe cardiac, hepatic, renal, or pulmonary dysfunction;
Glycated hemoglobin >9.0% at screening;
History of hypothalamic-pituitary related diseases or severe endocrine diseases;
Use of drugs affecting endocrine function (such as glucocorticoids, growth hormones) within the past six months;